ArticleBiomedical journal2026
Neuropeptide FF receptor 2 overexpression aggravates lipid accumulation and metabolic dysfunction in mice with diet-induced metabolic stress.
Article in Biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Displaced minds: ecologies of depression.Biomedical journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is a major contributor to metabolic dysfunction and is driven by complex genetic, behavioral, and physiological factors. Neuropeptide FF receptor 2 (NPFFR2) has been implicated in regulating feeding behavior, as well as energy and glucose homeostasis. However, its precise role in obesity and metabolic disorders remains unclear. This study aimed to investigate the systemic role of NPFFR2 in obesity-induced metabolic dysfunction. MATERIAL AND
methodsThe role of NPFFR2 was examined using wild-type and Npffr2-overexpressing transgenic mice subjected to 15 weeks of high-fat high-sucrose diet to induce obesity. Systemic, tissue-specific, and serum metabolic profiles were analyzed, with a particular focus on lipid abnormalities in the liver and adipose tissues.
resultsNpffr2 overexpression exacerbated obesity-induced metabolic dysfunction, including accelerated body weight gain, impaired glucose homeostasis, altered fat composition, adipose tissue inflammation, and dysregulated lipid metabolism. In addition, hypertrophy of both hepatocytes and adipocytes was aggravated in Npffr2-overexpressing mice, collectively contributing to excessive energy storage and reduced metabolic efficiency.
conclusionsThese findings suggest that NPFFR2 may contribute to the regulation of energy balance and lipid metabolism, potentially via central regulatory pathways. These findings highlight the need for mechanistic studies to clarify its region-specific roles and therapeutic potential in metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.